Dengue Testing Market By Test Type (ELISA, Rapid, PCR); By Sample Type (Blood, Serum); By Setting (Laboratory, Point-of-Care); By Target Marker (NS1, IgM, IgG); By Distribution Channel (Hospitals, Labs) – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Dengue Testing Market size was estimated at USD 1,140.66 million in 2025 and is expected to reach USD 1,752.54 million by 2032, growing at a CAGR of 7.42% from 2025 to 2032. Growing dengue incidence and wider geographic exposure are increasing demand for early confirmation to support triage, monitoring, and differential diagnosis in febrile patients. Faster deployment of point-of-care workflows, combined with expanding laboratory automation for confirmatory testing, is improving turnaround time and supporting higher seasonal testing volumes across endemic and travel-linked markets.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Dengue Testing Market Size 2025
USD 1,140.66 million
Dengue Testing Market, CAGR
7.42%
Dengue Testing Market Size 2032
USD 1,752.54 million
Key Market Trends & Insights
The Dengue Testing Market is forecast to grow from USD 1,140.66 million (2025) to USD 1,752.54 million (2032) at a 7.42% CAGR (2025–2032).
Asia Pacific accounted for the largest regional revenue share of 36.80% in 2025, supported by high testing volumes in endemic settings and seasonal outbreak peaks.
North America represented 31.60% revenue share in 2025, reflecting strong diagnostics access, surveillance readiness, and travel-related testing needs.
ELISA accounted for the largest share of 43.20% in 2025 as laboratories scaled standardized serology workflows for confirmatory testing and reporting.
Hospitals accounted for 44.30% in 2025 as acute-care triage and inpatient monitoring needs increased testing throughput during peak transmission periods.
Segment Analysis
Demand in the Dengue Testing Market is shaped by the need to detect infections across different disease windows and to support clinical decisions in both outpatient and inpatient settings. Early-stage testing tends to favor antigen and molecular approaches that can confirm probable cases quickly, while serology remains central for broader diagnostic coverage and confirmatory workflows. Buyers increasingly prioritize accuracy, speed, and workflow fit, with test selection varying by days post symptom onset, infrastructure availability, and staffing capacity.
Procurement patterns also reflect the need for surge capacity during outbreaks, making supply continuity and ease of deployment important differentiators. Point-of-care adoption improves access in decentralized settings, but laboratories remain essential for confirmatory testing, higher throughput, and standardized reporting. As public health surveillance improves, reporting integration and consistent quality systems become more influential in purchasing decisions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
ELISA accounted for the largest share of 43.20% in 2025. ELISA remains a primary choice for confirmatory workflows because laboratories can batch samples, standardize procedures, and maintain quality controls at scale. Serology testing also supports broader diagnostic coverage when patients present outside the early antigen detection window. Established lab networks and routine procurement cycles continue to reinforce ELISA utilization in high-volume settings.
By Sample Type Insights
Blood and serum usage is primarily determined by testing setting, collection practicality, and compatibility with assay workflows. Blood-based sampling supports rapid triage models where faster collection and immediate testing are required. Serum remains common in laboratory environments because many immunoassays and automated processes are optimized for standardized serum-based workflows. Sample transport, storage, and throughput requirements influence which sample type is prioritized across regions and channels.
By Setting Insights
Laboratory testing remains central for confirmatory diagnosis, quality-assured workflows, and reporting requirements, particularly during seasonal surges. Point-of-care testing expands access by reducing turnaround time and enabling faster clinical decision-making in decentralized environments. Adoption is influenced by staffing, training, quality assurance practices, and the ability to integrate results into clinical records and surveillance systems. The balance between laboratory and point-of-care usage varies by health system maturity and outbreak intensity.
By Target Marker Insights
NS1 accounted for the largest share of 40.10% in 2025. NS1 testing is strongly aligned with early detection needs, supporting faster triage and earlier clinical monitoring. Health systems often prefer early markers when case loads rise because prompt confirmation improves patient flow and resource planning. Continued efforts to improve assay specificity and operational reliability support ongoing adoption across both laboratory and point-of-care workflows.
By Distribution Channel Insights
Hospitals accounted for the largest share of 44.30% in 2025. Hospitals sustain high testing volumes because acute presentations require fast confirmation for triage, admission decisions, and monitoring of warning signs. Hospital procurement also favors products that can scale during outbreaks and fit existing clinical workflows. Laboratories remain essential partners for confirmation, batch processing, and standardized reporting, supporting integrated testing pathways across the care continuum.
Dengue Testing Market Drivers
Escalating dengue incidence and outbreak cyclicality
Rising dengue transmission and frequent outbreak cycles are increasing the baseline need for diagnostic confirmation across endemic and emerging risk areas. Health systems are prioritizing early diagnosis to improve patient triage and monitoring, especially during peak seasons when capacity constraints intensify. Increased testing also supports public health surveillance and outbreak response planning. These factors lift demand across rapid screening, serology confirmation, and molecular testing workflows.
For instance, Abbott’s Panbio Dengue Duo Cassette is designed to detect dengue NS1 antigen as well as IgM/IgG antibodies in about 20 minutes, which supports faster screening during outbreak-driven testing surges.
Greater emphasis on early confirmation and differential diagnosis
Clinical pathways increasingly require early confirmation to distinguish dengue from other febrile illnesses and to guide supportive care decisions. Early-stage detection strengthens adoption of NS1 and molecular testing approaches in both emergency and outpatient environments. Faster turnaround improves patient throughput and reduces uncertainty in initial care decisions. Broader adoption of structured testing algorithms supports sustained test utilization beyond peak outbreaks.
Expansion of decentralized testing and point-of-care access
Decentralized testing expands access in settings where laboratory infrastructure is limited or patient load is high. Point-of-care workflows reduce time to result and support faster triage, improving operational efficiency in community and outpatient settings. Deployment is supported by simpler sample handling and easier training requirements compared with complex laboratory methods. As access expands, demand grows for tests that remain accurate and consistent across varied operating conditions.
For instance, SD BIOSENSOR’s STANDARD Q Dengue Duo provides qualitative NS1, IgM, and IgG results in 15 to 20 minutes from whole blood, serum, or plasma, making it well suited to decentralized screening environments.
Scaling of laboratory automation and standardized workflows
Laboratory networks continue to invest in standardized workflows that improve throughput, quality controls, and reporting consistency. Automation supports batch testing during seasonal surges and helps address staffing constraints in high-volume facilities. Standardized lab methods also align with surveillance reporting needs and confirmation protocols. This driver reinforces demand for ELISA and complementary molecular confirmation tools in mature diagnostics ecosystems.
Dengue Testing Market Challenges
Performance variability across brands and operating conditions can reduce confidence and increase reliance on confirmatory testing. Serology interpretation challenges, including cross-reactivity and timing sensitivity, can complicate case confirmation and require more structured testing algorithms. Supply continuity risks during peak seasons can also disrupt testing access when demand spikes quickly. These issues can raise total testing cost, create delays, and reduce consistency in clinical decision-making.
For instance, bioMérieux states that its VIDAS dengue solution uses three independent and complementary assays, and its VIDAS DENGUE NS1 assay reported 96.4% overall percent agreement, while the combined IgG/IgM assay reported 91.9% positive percent agreement, with no cross-reactivity reported against chikungunya, Zika, yellow fever, or malaria, highlighting how manufacturers are trying to reduce interpretation complexity through multi-marker testing design.
Operational constraints remain significant in lower-resource settings, including gaps in trained staff, quality assurance, sample transport, and reporting infrastructure. Decentralized testing expansion can be limited by inconsistent oversight and difficulty maintaining standardized practices across dispersed sites. Reimbursement variability and fragmented procurement across hospitals, labs, and public agencies can slow adoption of higher-performance solutions. These barriers collectively constrain uniform testing access across regions.
Dengue Testing Market Trends and Opportunities
Integration of dengue testing into broader infectious disease workflows is expanding, with buyers favoring platforms and menus that support multi-pathogen diagnostics and streamlined operations. Laboratories are placing greater emphasis on workflow efficiency, reporting integration, and quality systems that can scale with outbreak volatility. This supports opportunities for automation-friendly assays, improved connectivity, and standardized operational support. Vendors that align products to real-world throughput needs can gain advantage in tender-driven purchasing.
For instance, Roche’s Elecsys Dengue Ag assay, designed for the cobas e 801 and cobas e 402 analyzers, delivers results in 18 minutes, supports throughput from 120 to 300 tests per hour, and demonstrated 94.90% sensitivity with 99.96% relative specificity in clinical studies, while Roche states that the fully automated workflow improves traceability and reduces manual activities and potential human error.
Point-of-care innovation remains an important opportunity, particularly for tests that improve ease of use, reliability, and result interpretation in decentralized settings. Growing emphasis on early detection supports continued product focus on acute-phase markers and faster time to result. Surveillance strengthening creates demand for data-ready testing solutions that support monitoring, trend analysis, and targeted interventions. These trends encourage product differentiation through workflow fit, quality support, and scalable deployment models.
Regional Insights
North America
North America accounted for 31.60% revenue share in 2025. The region benefits from strong diagnostics access, higher confirmatory testing penetration, and structured surveillance readiness that supports consistent demand outside peak travel periods. Healthcare systems emphasize quality assurance and integration into clinical workflows, which sustains utilization in laboratory settings. Testing demand is also supported by travel-linked screening and preparedness in areas with localized transmission risk.
Europe
Europe represented 13.40% revenue share in 2025. Demand is supported by travel-associated cases, targeted surveillance, and localized outbreaks in select geographies, with laboratories playing a central role in confirmation and reporting. Procurement tends to prioritize standardized performance and compliance-ready workflows. Public health coordination and centralized laboratory networks reinforce steady testing demand during seasonal risk periods.
Asia Pacific
Asia Pacific accounted for 36.80% revenue share in 2025, the largest regional share. High endemic burden, large population exposure, and strong seasonality create sustained testing volumes across hospitals, clinics, and public health channels. Rapid screening is important for triage during surges, while laboratory confirmation supports reporting and case management. Growth is supported by continued expansion of diagnostics access and surveillance capacity.
Latin America
Latin America held 12.70% revenue share in 2025. Outbreak volatility drives periodic testing surges that increase demand for scalable supply and fast turnaround. Hospital-centered testing volumes remain significant during peak periods, with lab networks supporting confirmation and reporting. Opportunities remain strong for solutions that expand decentralized access while maintaining consistent quality.
Middle East & Africa
Middle East & Africa accounted for 5.50% revenue share in 2025. Demand is influenced by uneven endemicity, variable surveillance maturity, and differences in laboratory capacity across countries. Rapid testing supports frontline triage in settings with limited infrastructure, while confirmatory capacity is often concentrated in fewer facilities. Expansion of quality systems and reporting pathways can improve adoption of more standardized testing approaches.
Competitive Landscape
Competition in the Dengue Testing Market is shaped by portfolio breadth across rapid tests, serology, and molecular solutions, along with channel strength and the ability to scale supply during seasonal surges. Vendors differentiate through assay reliability, workflow fit across point-of-care and laboratory settings, and operational support such as training and quality systems. Adoption is influenced by procurement preferences for standardized performance, integration into existing workflows, and dependable availability during outbreaks.
Abbott’s positioning reflects a focus on scalable diagnostics that fit high-throughput and frontline workflows, supported by broad commercialization reach. Abbott’s category strength is reinforced by products designed to support early detection and rapid triage needs, which align with seasonal outbreak patterns and acute-care demand. Execution advantages are typically linked to distribution coverage, supply continuity, and the ability to support consistent deployment practices across varied settings.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In October 2025, Roche said it received CE mark for its Elecsys Dengue Ag test, a fully automated high-throughput immunoassay for acute dengue diagnosis that can deliver results in 18 minutes, making it a notable recent product update in the dengue testing market.
In May 2025, SD Biosensor was part of a WHO and Medicines Patent Pool sublicensing agreement with Codix Bio to transfer rapid diagnostic test technology for local manufacturing in Nigeria, and this is relevant to dengue testing because SD Biosensor already markets dengue rapid diagnostic products such as the STANDARD F Dengue NS1 Ag FIA.
In November 2025, Group signed a strategic partnership with Certest Biotec to expand advanced laboratory solutions and introduce new CLIA systems in Saudi Arabia, and the development is relevant to the dengue testing market because Certest also offers the VIASURE Dengue Serotyping Real Time PCR Detection Kit.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 1,140.66 million
Revenue forecast in 2032
USD 1,752.54 million
Growth rate (CAGR)
7.42% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Test Type; By Sample Type; By Setting; By Target Marker; By Distribution Channel
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Dengue Testing Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Test Type
6.1. ELISA
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Rapid
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. PCR
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity 7. Market Breakup by Sample Type
7.1. Blood
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Serum
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup by Setting
8.1. Laboratory
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Point-of-Care
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity 9. Market Breakup by Target Marker
9.1. NS1
9.1.1. Market Trends
9.1.2. Market Forecast
9.1.3. Revenue Share
9.1.4. Revenue Growth Opportunity
9.2. IgM
9.2.1. Market Trends
9.2.2. Market Forecast
9.2.3. Revenue Share
9.2.4. Revenue Growth Opportunity
9.3. IgG
9.3.1. Market Trends
9.3.2. Market Forecast
9.3.3. Revenue Share
9.3.4. Revenue Growth Opportunity 10. Market Breakup by Distribution Channel
10.1. Hospitals
10.1.1. Market Trends
10.1.2. Market Forecast
10.1.3. Revenue Share
10.1.4. Revenue Growth Opportunity
10.2. Labs
10.2.1. Market Trends
10.2.2. Market Forecast
10.2.3. Revenue Share
10.2.4. Revenue Growth Opportunity 11. Market Breakup by Region
11.1. North America
11.1.1. United States
11.1.1.1. Market Trends
11.1.1.2. Market Forecast
11.1.2. Canada
11.1.2.1. Market Trends
11.1.2.2. Market Forecast
11.2. Asia-Pacific
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. South Korea
11.2.5. Australia
11.2.6. Indonesia
11.2.7. Others
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. United Kingdom
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Others
11.4. Latin America
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Others
11.5. Middle East and Africa
11.5.1. Market Trends
11.5.2. Market Breakup by Country
11.5.3. Market Forecast 12. SWOT Analysis
12.1. Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats 13. Value Chain Analysis 14. Porters Five Forces Analysis
14.1. Overview
14.2. Bargaining Power of Buyers
14.3. Bargaining Power of Suppliers
14.4. Degree of Competition
14.5. Threat of New Entrants
14.6. Threat of Substitutes 15. Price Analysis 16. Competitive Landscape
16.1. Market Structure
16.2. Key Players
16.3. Profiles of Key Players
16.3.1. Abbott
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. Financials
16.3.1.4. SWOT Analysis
16.3.2. Roche
16.3.3. Siemens Healthineers
16.3.4. Bio-Rad
16.3.5. SD Biosensor
16.3.6. Thermo Fisher
16.3.7. Qiagen
16.3.8. CTK Biotech
16.3.9. Euroimmun
16.3.10. InBios 17. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size and forecast for the Dengue Testing Market?
The Dengue Testing Market was valued at USD 1,140.66 million in 2025 and is projected to reach USD 1,752.54 million by 2032. The forecast reflects rising testing needs in endemic and travel-linked settings.
What is the growth rate for the Dengue Testing Market?
The Dengue Testing Market is expected to grow at a CAGR of 7.42% from 2025 to 2032. Growth is supported by higher outbreak testing volumes and broader surveillance activity.
What is the largest segment in the Dengue Testing Market?
ELISA is the largest test type, accounting for 43.20% share in 2025. High laboratory throughput and standardized serology workflows support continued leadership.
What factors are driving Dengue Testing Market growth?
Rising dengue incidence and expanding geographic exposure are increasing demand for earlier confirmation and structured testing algorithms. Expanded point-of-care access and laboratory automation are also strengthening testing capacity.
Who are the leading companies in the Dengue Testing Market?
Key companies include Abbott, Roche, Siemens Healthineers, Bio-Rad, SD Biosensor, Thermo Fisher, Qiagen, CTK Biotech, Euroimmun, and InBios. These firms compete through portfolio breadth and workflow fit across laboratory and point-of-care use.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Cutter Staplers Market size was estimated at USD 2,140.00 million in 2025 and is expected to reach USD 3,363.96 million by 2032, growing at a CAGR of 7.83% from 2025 to 2032.
The global Custom Procedure Packs Market size was estimated at USD 8,220.00 million in 2025 and is expected to reach USD 16,399.44 million by 2032, growing at a CAGR of 12.20% from 2025 to 2032.
The global Computed Tomography (CT) Market Market size was estimated at USD 9,070.00 million in 2025 and is expected to reach USD 13,234.42 million by 2032, growing at a CAGR of 6.50% from 2025 to 2032.
The global Cryosurgery Devices Market size was estimated at USD 712.63 million in 2025 and is expected to reach USD 1,044.52 million by 2032, growing at a CAGR of 6.58% from 2025 to 2032.
The global Cryostat Microbiome Equipment Market size was estimated at USD 468.92 million in 2025 and is expected to reach USD 737.53 million by 2032, growing at a CAGR of 7.84% from 2025 to 2032.
The global Cranial Fixation and Stabilization Systems Market size was estimated at USD 1,948.73 million in 2025 and is expected to reach USD 2,783.14 million by 2032, growing at a CAGR of 6.12% from 2025 to 2032.
The global Cruciate Ligament Repair Procedures Market size was estimated at USD 4,912.68 million in 2025 and is expected to reach USD 7,115.96 million by 2032, growing at a CAGR of 6.37% from 2025 to 2032.
The global Cranial Navigation System Market size was estimated at USD 1,586.42 million in 2025 and is expected to reach USD 2,404.92 million by 2032, growing at a CAGR of 7.18% from 2025 to 2032.
The global Cranial And Facial Implants Market size was estimated at USD 1,372.85 million in 2025 and is expected to reach USD 2,030.42 million by 2032, growing at a CAGR of 6.74% from 2025 to 2032.
The global Cranial Clamps Market size was estimated at USD 286.49 million in 2025 and is expected to reach USD 388.55 million by 2032, growing at a CAGR of 5.21% from 2025 to 2032.
The global Colposcopy Devices Market size was estimated at USD 606.81 million in 2025 and is expected to reach USD 862 million by 2032, growing at a CAGR of 5.14% from 2025 to 2032.
The global Collagen Dressings Market size was estimated at USD 2,332 million in 2025 and is expected to reach USD 3,631 million by 2032, growing at a CAGR of 6.53% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
